Research programme: small molecule therapeutics - BlueJay Therapeutics
Latest Information Update: 06 Mar 2024
At a glance
- Originator Bluejay Therapeutics
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 03 Jan 2024 Research programme: small molecule therapeutics - BlueJay Therapeutics is available for licensing as of 03 Jan 2024. https://bluejaytx.com/partnering/
- 03 Jan 2024 Preclinical trials in Liver disorders in USA (PO) before January 2024 (BlueJay Therapeutics pipeline, January 2024)